Press
Genomadix Secures First License of CubeX Platform and Divests Legionella Business to LuminUltra
Genomadix Secures First License of CubeX Platform and Divests Legionella Business to LuminUltra LuminUltra to Develop Menu of Portable PCR Products on the CubeX Platform OTTAWA, CANADA, September 9, 2024 – Genomadix (genomadix.com), the global leader in point of care precision medicine molecular diagnostics, today announced that it has licensed its CubeX Open Platform technology […]
Genomadix Eyes Expanded PGx Applications, Out licensing for Rapid PCR System
Genomadix Eyes Expanded PGx Applications, Out licensing for Rapid PCR System CEO, Steve Edgett, and Chief Scientific Officer, Jeremy Bridge-Cook sit down with GenomeWeb to share some groundbreaking developments at Genomadix. Check out the article below: Genomadix Eyes Expanded PGx Applications, Outlicensing for Rapid PCR System | GenomeWeb
Stanford Adds CYP2C19 Rapid Test to Genomics Menu, Plans Future PGx Expansion
Stanford Adds CYP2C19 Rapid Test to Genomics Menu, Plans Future PGx Expansion Stanford Medical Center has just introduced the Genomadix Cube and its rapid FDA-cleared CYP2C19 assay to their genomics lab. Check out the article below: Stanford Adds CYP2C19 Rapid Test to Genomics Menu, Plans Future PGx Expansion | GenomeWeb
Assets of Spartan Bioscience Inc. To Be Acquired By Casa-Dea Finance Limited
GENOMADIX ANNOUNCES SECURING TWO YEARS OF FUNDING Spartan Bioscience Inc. (Spartan) announces today that its primary assets will be acquired by a private company owned and led by Casa-Dea Finance Limited (Casa-Dea). In acquiring Spartan’s assets, Casa-Dea will strive to ensure that Spartan’s disruptive technology, and talented team of scientists, engineers and biotech professionals, will […]
GENOMADIX ANNOUNCES FDA CLEARANCE TO MARKET THE GENOMADIX CUBE CYP2C19 SYSTEM
GENOMADIX ANNOUNCES FDA CLEARANCE TO MARKET THE GENOMADIX CUBE CYP2C19 SYSTEM (OTTAWA, March 22, 2023) Genomadix , based in Ottawa, Canada, announced today the US Food and Drug Administration (FDA) granted 510(k) clearance permitting marketing of its “Genomadix CubeTM CYP2C19 System” (CubeTM CYP2C19 Test), an automated sample-to-result PCR test. The CubeTM CYP2C19 Test is indicated […]
Genomadix Inc. Announces Know-How License Agreement With Mayo Clinic
Genomadix Inc. Announces Know-How License Agreement with Mayo Clinic OTTAWA, ON, Aug. 29, 2022 /CNW/ – Genomadix today announced it has entered into a know-how license agreement and stock purchase agreement with Mayo Clinic to advance its point of care molecular analyzer technology. The Genomadix CubeTM uses polymerase chain reaction (PCR) technology in a small and portable […]